- Coriolis Pharma has opened its U.S. headquarters and laboratory at the Alexandria Center for Advanced Technologies in Research Triangle Park, North Carolina.
- The site will provide formulation development, particle analysis, and drug product development services for biopharmaceutical companies, with full capabilities expected by Q4 2026.
Coriolis Pharma has opened its U.S. headquarters and laboratory at the Alexandria Center for Advanced Technologies (ACAT) in Research Triangle Park (RTP), North Carolina, marking the start of operations at the new facility. The expansion is intended to provide North American clients with direct access to the company’s expertise in formulation and drug product development, as well as analytical characterisation of biopharmaceutical products.
The new laboratory will offer three core services: particle analysis and fast-track analytics, formulation development, and drug product development. These services will support activities ranging from high-precision particle identification and ad hoc non-GMP analytical testing to formulation work for liquid and frozen-liquid products, as well as primary packaging material selection and drug product filling process characterisation for regulatory submissions such as IND and BLA filings.
Coriolis said the services will be introduced progressively throughout 2026, with all capabilities expected to be available by the fourth quarter of the year. Certain fast-track analytical services have already begun supporting projects as of March 2026. The U.S. site will also work closely with the company’s headquarters in Germany and global partners to provide integrated support for biopharmaceutical development.
“Opening our lab and US Headquarter in North Carolina is a major leap forward for Coriolis. It fuels our mission to empower innovation where it happens. The region’s scientific excellence, cutting-edge biotech and manufacturing ecosystem and collaborative energy make it the perfect home for our next chapter.”
Silvia Steyrer-Gruber, CEO of Coriolis Pharma
The company said the expansion is intended to strengthen its ability to support biopharmaceutical development programs by providing local access to its services while maintaining collaboration with its global teams.
